The Motley Fool··Reuben Gregg BrewerAmarin's Vascepa Faces Generic Onslaught: Single-Drug Dependency Poses Existential Risk
Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.
PFEAMRNrevenue declinerestructuring